Literature DB >> 18095907

Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management.

Katherine W Phillips1, Jack Ansell.   

Abstract

Oral anticoagulation therapy with warfarin is the mainstay of prevention and treatment of thromboembolic disease. However, it remains one of the leading causes of harmful medication errors and medication-related adverse events. The beneficial outcomes of oral anticoagulation therapy are directly dependent upon the quality of dose and anticoagulation management, but the literature is not robust with regards to what constitutes such management. This review focuses on, and attempts to define, the parameters of high-quality anticoagulation management and identifies the appropriate outcome measures constituting high-quality management. Elements discussed include the most fundamental measure, time in therapeutic range, along with other parameters including therapy initiation, time to therapeutic range, dosing management when patients are not in therapeutic range, perioperative dosing management, patient education, and other important outcome measures. Healthcare providers who manage oral anticoagulation therapy should utilize these parameters as a measure of their performance in an effort to achieve high-quality anticoagulation management.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18095907     DOI: 10.1586/14779072.6.1.57

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  24 in total

Review 1.  Optimizing quality care for the oral vitamin K antagonists (VKAs).

Authors:  Vittorio Pengo; Gentian Denas
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Drug adherence in patients taking oral anticoagulation therapy.

Authors:  Sebastian Ewen; Volker Rettig-Ewen; Felix Mahfoud; Michael Böhm; Ulrich Laufs
Journal:  Clin Res Cardiol       Date:  2013-09-03       Impact factor: 5.460

3.  Use of vitamin K antagonist therapy in geriatrics: a French national survey from the French Society of Geriatrics and Gerontology (SFGG).

Authors:  Matthieu Plichart; Gilles Berrut; Nathalie Maubourguet; Claude Jeandel; Jean-Paul Emeriau; Joël Ankri; Hélène Bouvier; Geneviève Ruault; Olivier Hanon
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

4.  Clinical validation of a new algorithm for computerized dosing of vitamin K antagonist therapy: a retrospective simulation study.

Authors:  Michela Basileo; Carlo Micheluzzi; Marina Minozzi; Luigi Lazzaroni; Alfonso Iorio
Journal:  Intern Emerg Med       Date:  2011-04-06       Impact factor: 3.397

5.  What is the importance of real-time three dimensional transesophageal echocardiography and time in therapeutic range in patients with prosthetic valve thrombosis?

Authors:  Ahmet Guner; Macit Kalcik; Mustafa Ozan Gursoy; Sabahattin Gunduz; Mehmet Ozkan
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

6.  Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation.

Authors:  Scott Davis; Jane Gralla; Patrick Klem; Suhong Tong; Gina Wedermyer; Brian Freed; Alexander Wiseman; James E Cooper
Journal:  Am J Transplant       Date:  2017-10-24       Impact factor: 8.086

7.  Use of neutrophil-lymphocyte ratio for risk stratification and relationship with time in therapeutic range in patients with nonvalvular atrial fibrillation: A pilot study.

Authors:  Kahraman Cosansu; Mehmet Bulent Vatan; Huseyin Gunduz; Ramazan Akdemir
Journal:  Clin Cardiol       Date:  2018-03-22       Impact factor: 2.882

8.  Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial).

Authors:  Tetz C Lee; Min Qian; Gregory Y H Lip; Marco R Di Tullio; Susan Graham; Douglas L Mann; Koki Nakanishi; John R Teerlink; Ronald S Freudenberger; Ralph L Sacco; J P Mohr; Arthur J Labovitz; Piotr Ponikowski; Dirk J Lok; Conrado Estol; Stefan D Anker; Patrick M Pullicino; Richard Buchsbaum; Bruce Levin; John L P Thompson; Shunichi Homma; Siqin Ye
Journal:  Am J Cardiol       Date:  2018-06-04       Impact factor: 2.778

Review 9.  Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly.

Authors:  Kelechi C Ogbonna; Sean M Jeffery
Journal:  Drugs Aging       Date:  2013-07       Impact factor: 3.923

Review 10.  Point-of-care patient self-monitoring of oral vitamin K antagonist therapy.

Authors:  Jack Ansell
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.